首页> 美国卫生研究院文献>BioMed Research International >Elevated Ratio of Th17 Cell-Derived Th1 Cells (CD161+Th1 Cells) to CD161+Th17 Cells in Peripheral Blood of Early-Onset Rheumatoid Arthritis Patients
【2h】

Elevated Ratio of Th17 Cell-Derived Th1 Cells (CD161+Th1 Cells) to CD161+Th17 Cells in Peripheral Blood of Early-Onset Rheumatoid Arthritis Patients

机译:早期类风湿关节炎患者外周血中Th17细胞衍生的Th1细胞(CD161 + Th1细胞)与CD161 + Th17细胞的比例升高

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the destruction of articular cartilage and bone with elevated levels of proinflammatory cytokines. It has been reported that IL-17 and Th17 cells play important roles in the pathogenesis of RA. Recently, plasticity in helper T cells has been demonstrated; Th17 cells can convert to Th1 cells. It remains to be elucidated whether this conversion occurs in the early phase of RA. Here, we tried to identify Th17 cells, Th1 cells, and Th17 cell-derived Th1 cells (CD161+Th1 cells) in the peripheral blood of early-onset RA patients. We also evaluated the effect of methotrexate on the ratio of Th17 cells in early-onset RA patients. The ratio of Th17 cell-derived Th1 cells to CD161+Th17 cells was elevated in the peripheral blood of early-onset RA patients. In addition, MTX reduced the ratio of Th17 cells but not Th1 cells. These findings suggest that IL-17 and Th17 play important roles in the early phase of RA; thus, anti-IL-17 antibodies should be administered to patients with RA in the early phase.
机译:类风湿关节炎(RA)是一种慢性炎症性疾病,其特征是关节软骨和骨骼受到破坏,促炎性细胞因子水平升高。据报道,IL-17和Th17细胞在RA的发病中起重要作用。最近,已经证明了辅助性T细胞的可塑性。 Th17细胞可以转化为Th1细胞。这种转化是否发生在RA的早期尚待阐明。在这里,我们试图鉴定早期RA患者外周血中的Th17细胞,Th1细胞和Th17细胞衍生的Th1细胞(CD161 + Th1细胞)。我们还评估了甲氨蝶呤对早发性RA患者Th17细胞比例的影响。早期RA患者外周血中Th17细胞来源的Th1细胞与CD161 + Th17细胞的比例升高。此外,MTX降低了Th17细胞的比例,但没有降低Th1细胞的比例。这些发现表明IL-17和Th17在RA的早期阶段起着重要的作用。因此,抗IL-17抗体应在RA早期给予RA患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号